Additional file 2: Figure S3. of New insights into the pharmacokinetics and pharmacodynamics of natalizumab treatment for patients with multiple sclerosis, obtained from clinical and in vitro studies

Sehr, T.; Proschmann, U.; Thomas, K.; Marggraf, M.; Straube, E.; Reichmann, H.; Chan, A.; Ziemssen, T.

doi:10.6084/m9.figshare.c.3623027_D2.v1

12974_2016_635_MOESM2_ESM.pptx (45.73 kB)

Additional file 2: Figure S3. of New insights into the pharmacokinetics and pharmacodynamics of natalizumab treatment for patients with multiple sclerosis, obtained from clinical and in vitro studies

presentation

posted on 2016-06-27, 05:00 authored by T. Sehr, U. Proschmann, K. Thomas, M. Marggraf, E. Straube, H. Reichmann, A. Chan, T. Ziemssen

Correlation of pre- and post-serum values at both timepoints. Correlation of pre- (black circle) and post- (white circle) NAT serum values at timepoint 0 and after 1 year (+1a). r = Spearman’s rank correlation coefficient, p = p value of significance. (PPTX 45 kb)